More info
Assay Range | 62.5--4000 pg/mL |
Sensitivity | 10.0 pg/mL |
Size | 96T |
Storage | Store at 2 - 8ºC. Keep reconstituted standard and detection Ab at -20 ºC |
Assay Principle | Sandwich ELISA |
Sample volume | 100 µL final volume, dilution factor varies on samples |
Detection Method | Chromogenic |
Kit Components
1. Recombinant Human FLRG standard: 2 vials
2. One 96-well plate precoated with anti- Human FLRG Ab
3. Sample diluent buffer: 12 mL - 1
4. Detection antibody: 130 µL, dilution 1:100
5. Streptavidin-HRP: 130 µL, dilution 1:100
6. Antibody diluent buffer: 12 mL x1
7. Streptavidin-HRP diluent buffer: 12 mL x1
8. TMB developing agent: 10 mL x1
9. Stop solution: 10 mL x1.
10. Washing solution (20x): 25 mL x1.
Background
Follistatin-related Gene (FLRG), also known as Follistatin-like 3 (FSTL3) and Follistatin-related protein (FSRP), is a secreted glycoprotein encoded by the FSTL3 gene in humans. Mature human FLRG consists of an Activin and Myostatin binding N-terminal domain, two Follistatin-like domains, and two Kazal-like domains. FLRG is expressed in the uterus, ovary, testis, placenta, trophoblast, and adrenal gland. It is upregulated in cardiac myocytes following myocardial injury and blocks the prosurvival and anti-hypertrophic effects of Activin A on these cells. FLRG is also expressed by astroglial cells in areas of neuronal trauma. FLRG is a binding and antagonizing protein for members of the TGF-beta family, such as activin, BMP2 and MSTN. It inhibits activin A-, activin B-, BMP2- and MSDT-mediated cellular signaling cascades. Its binding to ADAM12 as well as to Activin A inhibits osteoclastic differentiation from macrophages. It is shown that FLRG may play a role in promoting bone formation, inhibiting osteoclast differentiation, participating in hematopoiesis and differentiation of hemopoietic progenitor cells, as well as increasing hematopoietic cell adhesion to fibronectin.